Search

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
GET IN TOUCH
Case Study

Case Study - Elevating Purity Levels: Racemizing Pharmaceutical Products in Advanced Flow Microreactors

Download PDF

Racemization involves transforming an optically active compound into its racemic (optically inactive) counterpart through either heat or a chemical reaction. This results in an equal 1:1 ratio of enantiomers, forming what is known as a racemic mixture. Typically, reactions are specific to one stereoisomer, leading to the desired product, while the other stereoisomer remains unreactive or might trigger undesired side effects.

This case study presents a project executed by Aragen’s experts in process development and scale-up. The project’s aim was to carry out the racemization of an undesired compound. This compound was synthesized by the client for treating inflammatory conditions. The client encountered a challenge as they couldn’t successfully generate the racemic mixture of the compound during batch racemization processes, and the compound’s purity was declining. Given Aragen’s expertise in racemization, they were approached to help achieve the biologically active racemic mixture while maintaining the compound’s purity

The Project:

To perform racemization of an unwanted compound to achieve a biologically active racemic mixture with high purity. The project involved two stages: initial experimentation in a batch system to identify and understand the challenges faced, and subsequent implementation in a flow system. The transition to the flow system served a dual purpose – addressing challenges encountered in the batch setup and enabling the scalability of the process for large-scale production of the compound while maintaining the purity.

About the client:

The client is a biotechnology company headquartered in the United States, specializing in drug research and development especially focusing on creating innovative small-molecule therapies for immune-inflammatory conditions.

Aragen’s Approach:

Batch experiments: Undesired compound was taken in 15 vol. of toluene and heated to reflux for 5-6 hrs.

Issue in batch racemization: Due to longer exposure under reflux conditions purity of compound decreased from 99.7% to 92% as indicated by HPLC analysis.

Flow experiments:

The undesired compound was dissolved in 22vol of Acetonitrile (ACN) at 25-30°C and was passed through Corning flow reactor at 180°C under back pressure of 11 Bar. (schematic representation: Figure 1)

Residence time: 5.4 min

Flow rate: 0.5 mL/min

 

Figure 1: Schematic representation of the flow-setup for performing Racemization in advanced flow microreactors
Project outcome:
  • Complete racemization achieved at temperature 180°C and residence time of 5.4 min.
  • Compound purity remains above 99.5%, attributed to the less exposure time in flow reactor.
  • Continuous outlet stream of racemized reaction mass can be connected to a separation unit.
  • Operation at 180°C was compensated by back pressure regulator to avoid any boiling of solvent.
Aragen Advantage:
  • Availability of a range of advanced microreactors with varying channel dimensions.
  • Tubular flow crystallizer with mixing by design
  • Fixed Bed Reactor (up to 250 mL fixed bed column)
  • Greener approach with capabilities encompassing screening, lab development and piloting
  • Capability to process multi kilograms scale (up to 5-10 Kg)
  • Dedicated team of experts for flow process development
  • Strong collaboration with leading flow reactor vendors
  • Proven track record in technical problem-solving for leading global pharma and biotech companies To know more about our flow chemistry expertise or to speak with our subject experts, write to us at bd@aragen.com.